Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294740826> ?p ?o ?g. }
- W4294740826 endingPage "10038" @default.
- W4294740826 startingPage "10038" @default.
- W4294740826 abstract "Hepatocellular carcinoma (HCC) is the second most lethal tumor, with a 5-year survival rate of 18%. Early stage HCC is potentially treatable by therapies with curative intent, whereas chemoembolization/radioembolization and systemic therapies are the only therapeutic options for intermediate or advanced HCC. Drug resistance is a critical obstacle in the treatment of HCC that could be overcome by the use of targeted nanoparticle-based therapies directed towards specific tumor-associated antigens (TAAs) to improve drug delivery. Glypican 3 (GPC3) is a member of the glypican family, heparan sulfate proteoglycans bound to the cell surface via a glycosylphosphatidylinositol anchor. The high levels of GPC3 detected in HCC and the absence or very low levels in normal and non-malignant liver make GPC3 a promising TAA candidate for targeted nanoparticle-based therapies. The use of nanoparticles conjugated with anti-GPC3 agents may improve drug delivery, leading to a reduction in severe side effects caused by chemotherapy and increased drug release at the tumor site. In this review, we describe the main clinical features of HCC and the common treatment approaches. We propose the proteoglycan GPC3 as a useful TAA for targeted therapies. Finally, we describe nanotechnology approaches for anti-GPC3 drug delivery systems based on NPs for HCC treatment." @default.
- W4294740826 created "2022-09-06" @default.
- W4294740826 creator A5016085898 @default.
- W4294740826 creator A5017959340 @default.
- W4294740826 creator A5028533961 @default.
- W4294740826 creator A5067110431 @default.
- W4294740826 creator A5068048791 @default.
- W4294740826 date "2022-09-02" @default.
- W4294740826 modified "2023-10-05" @default.
- W4294740826 title "Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies" @default.
- W4294740826 cites W1132077651 @default.
- W4294740826 cites W115125409 @default.
- W4294740826 cites W1502988744 @default.
- W4294740826 cites W1577566545 @default.
- W4294740826 cites W1883333379 @default.
- W4294740826 cites W1892226266 @default.
- W4294740826 cites W1960912034 @default.
- W4294740826 cites W1961598420 @default.
- W4294740826 cites W1963615455 @default.
- W4294740826 cites W1963987641 @default.
- W4294740826 cites W1967952913 @default.
- W4294740826 cites W1971837077 @default.
- W4294740826 cites W1972875962 @default.
- W4294740826 cites W1973108158 @default.
- W4294740826 cites W1973524221 @default.
- W4294740826 cites W1976801200 @default.
- W4294740826 cites W1977093559 @default.
- W4294740826 cites W1978678628 @default.
- W4294740826 cites W1980734717 @default.
- W4294740826 cites W1983457010 @default.
- W4294740826 cites W1985777811 @default.
- W4294740826 cites W1995040137 @default.
- W4294740826 cites W1996697333 @default.
- W4294740826 cites W1996998905 @default.
- W4294740826 cites W2002533120 @default.
- W4294740826 cites W2005335309 @default.
- W4294740826 cites W2009013652 @default.
- W4294740826 cites W2009805582 @default.
- W4294740826 cites W2011100088 @default.
- W4294740826 cites W2012899811 @default.
- W4294740826 cites W2020398834 @default.
- W4294740826 cites W2027463801 @default.
- W4294740826 cites W2035342960 @default.
- W4294740826 cites W2035962912 @default.
- W4294740826 cites W2045798638 @default.
- W4294740826 cites W2048879854 @default.
- W4294740826 cites W2049388096 @default.
- W4294740826 cites W2050172553 @default.
- W4294740826 cites W2050742355 @default.
- W4294740826 cites W2051402860 @default.
- W4294740826 cites W2054745605 @default.
- W4294740826 cites W2056621404 @default.
- W4294740826 cites W2058388773 @default.
- W4294740826 cites W2060322741 @default.
- W4294740826 cites W2072009837 @default.
- W4294740826 cites W2077790222 @default.
- W4294740826 cites W2082511916 @default.
- W4294740826 cites W2091425194 @default.
- W4294740826 cites W2093538839 @default.
- W4294740826 cites W2096866380 @default.
- W4294740826 cites W2097603366 @default.
- W4294740826 cites W2099417196 @default.
- W4294740826 cites W2100173894 @default.
- W4294740826 cites W2100393769 @default.
- W4294740826 cites W2106285087 @default.
- W4294740826 cites W2107118584 @default.
- W4294740826 cites W2113530405 @default.
- W4294740826 cites W2115794657 @default.
- W4294740826 cites W2125410856 @default.
- W4294740826 cites W2125489343 @default.
- W4294740826 cites W2126330431 @default.
- W4294740826 cites W2132286877 @default.
- W4294740826 cites W2134589440 @default.
- W4294740826 cites W2134726513 @default.
- W4294740826 cites W2135518010 @default.
- W4294740826 cites W2140527988 @default.
- W4294740826 cites W2143463421 @default.
- W4294740826 cites W2151600653 @default.
- W4294740826 cites W2152478396 @default.
- W4294740826 cites W2154200023 @default.
- W4294740826 cites W2154881868 @default.
- W4294740826 cites W2159848663 @default.
- W4294740826 cites W2170369650 @default.
- W4294740826 cites W2170845559 @default.
- W4294740826 cites W2187002261 @default.
- W4294740826 cites W2277004004 @default.
- W4294740826 cites W2280132335 @default.
- W4294740826 cites W2307277127 @default.
- W4294740826 cites W2337468808 @default.
- W4294740826 cites W2341498785 @default.
- W4294740826 cites W2381727044 @default.
- W4294740826 cites W2408088858 @default.
- W4294740826 cites W2413809012 @default.
- W4294740826 cites W2474964647 @default.
- W4294740826 cites W2491724962 @default.
- W4294740826 cites W2526039053 @default.
- W4294740826 cites W2554165867 @default.
- W4294740826 cites W2560499218 @default.